Branded

Pfizer, Astellas obtain FDA OK for Xtandi
Xtandi is the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer.
IQVIA report analyzes drug shortages in the U.S.
Over the past five-and-a-half years, an average of more than 25 new molecule shortages have occurred annually, with 160 in total added through June of 2023 and only 51 resolved.

Eli Lilly gets FDA nod for Zepbound for chronic weight management
The FDA has approved Eli LIlly's Zepbound for chronic weight management in adults with obesity, in addition to a reduced calorie diet and increased physical activity.
Zydus receives FDA OK for Zituvio
Zituvio is used to treat adult patients with Type 2 diabetes mellitus.
Sun Pharma Canada’s Winlevi rolls out in Canada
Winlevi is the first and only topical androgen receptor inhibitor, and the newest Health Canada-approved formulation to target the hormonal component of acne in 40 years.
Phathom Pharmaceuticals receives FDA nod for Voquezna
Voquezna is a new treatment for adults for the healing and maintenance of all grades of erosive esophagitis.
Eli Lilly obtains FDA OK for Omvoh
Omvoh is a treatment for adults with moderate to severe ulcerative colitis.
Elsevier launches PharmaPendium
Elsevier’s PharmaPendium aims to empower pharma companies to bring novel drugs to market faster and increase success of regulatory submissions.
GoodRx offers Sanofi’s Lantus for $35 at more than 70,000 pharmacies
Americans with a valid prescription, regardless of insurance status, can use GoodRx to access a 30-day supply of Lantus for $35.
Santhera receives FDA nod for Agamree
Agamree is used to treat Duchenne muscular dystrophy in patients 2 years of age and older.

Pfizer, Astellas obtain FDA OK for Xtandi